World Health Organization Report - AI in Pharma: Benefits, Risks, and Governance
2025/02/27
再生時間： 19 分
ポッドキャスト

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

World Health Organization Report - AI in Pharma: Benefits, Risks, and Governance

無料で聴く

ポッドキャストの詳細を見る

サマリー
This World Health Organization (WHO) report explores the potential benefits and risks of using artificial intelligence (AI) in the creation and distribution of pharmaceuticals. It examines how AI is currently being used in the drug development lifecycle, from initial research to post-market monitoring, and considers the ethical challenges that arise. The report analyzes whether the commercial application of AI is truly beneficial for public health, highlighting potential biases and inequities. It also emphasizes the necessity of maximizing the positive public health outcomes of AI in pharmaceutical development while responsibly addressing risks and challenges. Governance of data, intellectual property, and private sector involvement is also discussed, along with regulatory oversight. The document concludes by outlining the next steps needed to ensure AI serves the public interest in the pharmaceutical field, emphasizing the importance of governance and ethical standards.

続きを読む一部表示

あらすじ・解説

This World Health Organization (WHO) report explores the potential benefits and risks of using artificial intelligence (AI) in the creation and distribution of pharmaceuticals. It examines how AI is currently being used in the drug development lifecycle, from initial research to post-market monitoring, and considers the ethical challenges that arise. The report analyzes whether the commercial application of AI is truly beneficial for public health, highlighting potential biases and inequities. It also emphasizes the necessity of maximizing the positive public health outcomes of AI in pharmaceutical development while responsibly addressing risks and challenges. Governance of data, intellectual property, and private sector involvement is also discussed, along with regulatory oversight. The document concludes by outlining the next steps needed to ensure AI serves the public interest in the pharmaceutical field, emphasizing the importance of governance and ethical standards.

続きを読む一部表示